Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessing Etentamig (ABBV-383) as an IV infusion, alone or in combination with Daratumumab, Lenalidomide, Dexamethasone, and Carfilzo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Etentamig (ABBV-383) (Etentamig)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING